The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH AL 2020 | AML: genetic screening and subtypes
Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, highlights the importance of genetic screening in acute myeloid leukemia (AML). Additionally, Dr Daver discusses what AML subtypes to test in order to choose treatment options, improve outcomes, and reduce treatment-related toxicities. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
